Clinical Trial

A Study of BPI-460372 in Advanced Solid Tumor Patients

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated January 27, 2025 (before its estimated April 17, 2025 completion). Its status may not reflect the trial's current state.
Summary
This study is an open-label, single arm, dose escalation and dose expansion phase 1 study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of BPI-460372 in solid tumor patients.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-03-16; most recent amendment 2025-01-22.
Status change: Not Yet Recruiting → Recruiting 2024-02-05
Trial Details
NCT Number NCT05789602
Lead Sponsor Betta Pharmaceuticals Co., Ltd.
Conditions Advanced Solid Tumor
Enrollment 82 participants
Start Date 2023-04-24
Primary Completion 2025-04-17 (estimated)
Study Completion 2026-04-17 (estimated)
Updated on ClinicalTrials.gov 2025-01-27